Inherited gene variants linked to higher cancer risk
In Penn Medicine Biobank, carriers had 3.41 times the odds of a cancer diagnosis compared with non-carriers.
Our read
Populations- Studied:
- Preprint: cohort study of 469,558 people
- In the record:
- The 9th paper on POT1 with results in people; 53 on record in all.
Editor of record: Boris Djordjevic · AgingResearch.News
People in three biobanks and a Penn Medicine clinical cohort were assessed in an observational study of inherited variants in POT1, a gene associated with cancer susceptibility. The biobanks included 51,172 people at Penn Medicine, 220,582 at Geisinger MyCode and 469,558 in UK Biobank.
The researchers estimated that one in 1,279 to one in 2,902 people carried the variants. Carriers had higher odds of a cancer diagnosis than non-carriers in all three biobanks. Cancer incidence increased beginning in the mid-30s, without evidence of increased mortality. Lung cancer was among the cancers associated with the variants in two biobanks.
Why it matters
Inherited cancer susceptibility raises questions about when risk emerges over a lifetime. The authors said these data could help inform clinical management.
Caveats
Cancer risk in these biobank and clinical cohorts may not match risk in the wider population. The findings are from a preprint that has not been peer-reviewed.
The paper
Cancer risk and survival outcomes in germline POT1 variant carriers
University of Pennsylvania
medRxiv, Nov 12, 2026, Open access, CC BY-NC-ND, Preprint, not yet peer-reviewed
Comments
Be the first to comment.